Introduction

B
iomedical imaging has revolutionized our understanding of cancer biology, and with it, our ability to examine preclinical models of malignant growth. Intravital fluorescence microscopy can be used to study diverse biological processes at the cellular level [1] . Positron emission tomography (PET) can report on the distribution of cells and drugs on a whole-body level [2] . In the clinic and in medical practice, PET imaging has proven to be an invaluable source of the information necessary for the effective diagnosis and staging of disease [2, 3] . For these reasons, highly specific molecular biomarkers have, along with advancing detection technologies, become increasingly important in the standard of care for cancer treatment [4] .
PET in particular has become one of the most prevalent clinical imaging modalities, emerging as one of the key diagnostic tools for whole-body imaging of cancer in the clinic. PET imaging is highly sensitive as well as quantitative and provides a resolution of tumors on a lesionby-lesion basis. However, the technology does not outperform other imaging technologies in every aspect. PET is expensive, it exposes the patient to ionizing radiation, and it has poor temporal and spatial resolution [5, 6] .
Several features of intraoperative fluorescence imaging are orthogonal to PET: the fluorescently emitted light-typically in the visible and near-infrared (NIR) range-is heavily attenuated, which prevents deep-tissue imaging. However, intraoperative fluorescence imaging provides much higher (up to sub-cellular) resolution and has recently been used to add artificial optical contrast during surgical interventions [7, 8] . This technique could become an important tool in the operating room and help to achieve more complete tumor resections, but it still lacks the deep tissue penetration to discover growths buried deep in the patient tissue as PET imaging is able to do.
The creation of targeted bimodal probes, which fuse the benefits of different types of imaging agents, could lead to better and more accurate location of diseased tissue [9, 10] . Target specificity is critical to the efficacy of these probes. Other novel bimodal probes for PET/epifluorescence imaging that target the GLP-1 receptor, a cell surface marker overexpressed in insulinoma, have been described [11] . Other imaging agents make use of the enhanced permeability and retention (EPR) effect [12] , which allows an imaging agent to be delivered to lesions via a physiological property rather than the expression of a specific molecular marker [13] . Recently, it was demonstrated that enhanced fluorescent contrast agents facilitate more complete resection of glioblastoma. The use of contrast-enhancing 5-aminolevulinic acid during neurosurgical resections of glioblastoma resulted in a 6-month improved progressionfree survival [8] .
Artificial bimodal intraoperative and deep tissue contrast could ultimately become particularly important for the surgical resection of glioblastoma, a highly infiltrative disease, where resection often remains incomplete [14] [15] [16] . Different reports have shown that the nuclear DNA repair enzyme PARP1 is overexpressed in a variety of diseases and that the expression levels of PARP1 have prognostic value [17] [18] [19] [20] . This is evidenced in brain malignancies with elevated rates of PARP1 that contrast significantly with the low PARP1 protein content in healthy brain tissue [21, 22] . Following these findings, we have shown that the elevated PARP1 expression can be exploited to image glioblastoma in mouse models of cancer with PARPi-FL, a fluorescently labeled PARP1-targeted imaging agent [23] [24] [25] . Similar to other fluorescent imaging agents, however, the tissue penetration depth of PARPi-FL is limited. Therefore, we hypothesized that a bimodal version of this small molecule would allow the detection of glioblastoma-both noninvasively using PET and at high resolution using fluorescence imaging. The goal of the current study was to use a 18 F/ 19 F exchange reaction [26] [27] [28] [29] to transform the fluorescent PARPi-FL molecule into a structurally identical but PET-active imaging agent, [ 18 F]PARPi-FL [29] . In the current study, we show that the PARPi-FL can be radiolabeled and used to augment the limitations of the Bfluorescence only^intraoperative imaging molecule. We predict that a bimodal-targeted PARP1 imaging agent will be beneficial as a standard of care diagnostic agent while also being useful for the identification of surgical tissue margins at high resolution and the deep tissue delineation of malignant growth.
Materials and Methods
A detailed description of synthetic procedures, radiosynthesis, and in vitro and in vivo experiments can be found in the supplemental data. All animal experiments were done in accordance with protocols approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center and followed National Institutes of Health guidelines for animal welfare.
Results
Radiosynthesis of [
18 F]PARPi-FL1 The molecular structure of PARPi-FL is based on the PARP1 inhibitor Olaparib [25, 30] . Figure 1a (Fig. 1a, bottom) . Based on previous reports [26] [27] [28] [29] , we devised an automated strategy to generate the radiolabeled bimodal [
18 F]PARPi-FL (Fig. 1b) [40. 6±3.3 % with 10 eq. SnCl 4 (μmol)/PARPi-FL (μmol)]. The specific activity was proportional to the activity of added 18 F. With increasing temperature and SnCl 4 , the yields decreased, presumably due to larger fractions of PARPi-FL being subjected to degradation. Longer reaction times did not markedly increase the labeling yield. The automated [
18 F]PARPi-FL synthesis was beneficial compared to the manual process (Table S1 ). Based on our screening, we were able to increase the specific activity by 266 % (from 3 to 9 mCi/μmol). The isolated radiochemical yields were increased by 187 % (from 23 to 43 %). Finally, the automated synthetic process was faster, allowing the 18 FPARPi-FL synthesis to be performed in only 70 min (90 min for manual synthesis). Immunohistochemistry and Autoradiography Using histological sections of healthy mouse brain and U87 MG glioblastoma xenografts, we showed that the PARP1 expression in the U87 MG tissues is increased by a factor of 11.4 (17.1±1.6 and 1.5±0.9 % PARP1-positive area for U87 MG and healthy mouse brains, respectively, Fig. S4 (blocked) . Autoradiography showed a homogeneous distribution of radioactivity in the tumors of non-blocked mice (Fig. 4a) . The uptake in tumors of blocked mice was markedly lower, with an overall reduction of 80± F]PARPi-FL in the tumor was higher than the observed accumulation in brain and muscle in both surface fluorescence imaging (tumor to brain ratio was sevenfold increased) and autoradiography (tumor to brain ratio was ninefold higher) (Fig. 5a-c) . The differences in imaging ratios (sevenfold versus ninefold) are likely due to the differences in penetration depths and readout techniques for the two imaging modalities.
Olaparib-blocked organs showed greatly reduced uptake in the tumor (74 ±12 and 66±9 % reduction for surface fluorescence imaging and autoradiography, respectively). Line profiles of tumors and brains were obtained with both imaging techniques. Autoradiographic staining and epifluorescence imaging provided corresponding organ uptake profiles (Fig. 5d, e) . These results indicate that [ shoulder of tumor-bearing mice in both coronal and axial PET/CT reconstructions (Fig. 6a) . The uptake of [ 18 F]PARPi-FL in U87 MG tumors was 0.78±0.1, which we were able to reduce to 0.15±0.06 by blocking with an excess of Olaparib (500 mM, 3.7 μmol, in 100 μl 15 % PEG300/85 % 0.9 % saline), similar to what has been done before [24] . The standardized uptake value (SUV) in U87 MG tumors was 1.10±0.53, which also could be reduced to 0.10 ±0.06 by blocking pre-injection of an excess of Olaparib (50-fold). PET imaging revealed a high uptake in the liver and in the intestinal tract, which is consistent with hepatobiliary excretion and analogous to what we and others have seen for monomodal radiolabeled PARP1 imaging agents [31, 32] (Fig. 6a, b) . Activity was also observed in the bone and junctures, typically a result of defluorination of radiolabeled imaging agents during metabolic degradation. Blood Half-Life and Biodistribution In order to explore the potential in vivo applications of [ 18 F]PARPi-FL as a multimodality imaging probe, we evaluated its blood halflife (Fig. 6c) . After tail vein injection of [ 18 F]PARPi-FL (27 μCi, 100 μl), the observed weighted t 1/2 was 15.6 min. The calculated tumor uptake in the positive control group, at 90 min p.i., was 0.78±0.1 %injected dose/gram (%ID/g). Tumor uptake dropped to 0.1±0.02 %ID/g at 90 min p.i. for mice that received a pre-injection of Olaparib. For each group, liver and kidney uptake of the radiotracer was lower in mice receiving a pre-injection of Olaparib, indicating specific binding of the tracer to a certain extent additionally to the uptake due to excretion. (Liver 3.8±0.4 and 2.02± 0.2 %ID/g, PG0.001 and kidneys 0.7±0.1 and 0.4±0.1 %ID/g, PG0.05, for non-blocked and blocked, respectively) (Fig. 6d) . The tumor to muscle ratio of [ 18 F]PARPi-FL was 4±0.6 at 90 min post injection. The tumor to brain tissue ratio of 12±2.1 (Fig. 6e) indicates a significant potential clinical value for the probe.
Discussion
The primary objective of this study was to explore the synthesis and in vivo pharmacokinetics of [ 18 F]PARPi-FL as a potential bimodal PET/optical imaging agent for PARP1-targeted imaging of glioblastoma. In recent years, PARP1 therapeutics have been a major focus in biomedical and pharmaceutical research [33, 34] . This focus is reflected in the number of PARP1 therapeutics which are currently being evaluated in clinical trials (e.g., the three PARP1 therapeutics Olaparib [35] , Niraparib [36] , and BMN673 [37] have entered phase III trials). Moreover, Olaparib (Lynparza TM ) was recently approved as a monotherapy for patients with advanced ovarian cancer by the FDA. In addition to the therapeutic value of PARP1 inhibition, the enzyme may also prove to be a valuable target for diagnostic and prognostic tools. It has already been shown to be a powerful diagnostic target for the delineation of glioblastoma [21, 22] , [24] . Our central hypothesis is that an 18 F-labeled PARPi-FL might enable imaging of brain tumors with high contrast values, even if their growth in the clinic is highly diffuse and poorly differentiated [38, 39] . SnCl 4 was used to facilitate the 19 F/ 18 F trans-fluorination of the BODIPY-FL group on the PARP1 tracer. The Lewis acid, together with the starting activity of 18 F − , has been confirmed to be one of the critical parameters in the tracer synthesis. Increasing amounts of SnCl 4 cause an increase in specific activity (5.02±0.56 for 50 eq. SnCl 4 versus 8.55±0.35 for 150 eq. SnCl 4 ), which might be due to increased degradation of the starting material before 18 F is added to the mixture. This is also confirmed by decreasing radiochemical yields (Fig. 3 ). Similar effects were described and observed by Conti and colleagues [26] , and we observed high amounts of radiolabeled, as well as cold by-product formation, with increasing amounts of added SnCl 4 . Similarly, the amount of [ 18 F]fluoride (n.c.a.) effects both radiochemical yield and specific activity because increasing ratios of 18 F/ 19 F will also increase the probability of successful incorporation of the isotope. In agreement with expectation, the radiochemical yield and specific activity were both highly dependent on reaction volume (and therefore reactant concentration). For both reaction time and temperature, there are optimal values in which there is enough time and energy for the reaction to proceed without side-product formation to become a dominant reaction pathway.
It was our aim to develop an automated Bone-potp rocedure for the synthesis of 18 F-PARPi-FL. A one-pot strategy is desired for radiochemical synthesis with shortlived isotopes, which typically reduces the overall synthesis time and results in higher isolated radiochemical yields.
Using the values obtained in the optimization procedure, the tracer was synthesized, purified, and formulated within 70 min, using an automated reaction protocol, allowing for clinical translation. The replacement of a 19 F with an 18 F isotope quickly yielded the final product with a good radiochemical yield (around 30.3±7.3 % dcRCY) and high radiochemical purity (≥98 %). The specific activity was below 200 mCi/μmol, similar to other previously observed 18 F/ 19 F trans-fluorinations [26] . The lower specific activity of [ 18 F] 18 F-PARPi-FL relative to other clinical 18 F-labeled PET imaging agents is due to structural equivalence of the precursor PARPi-FL and the radiolabeled product, which makes separation not possible. Its specific activity, however, does not reduce the value of this tracer since a bimodal optical/PET imaging agent requires higher concentrations than a monomodal PET agent to obtain sufficient signal/ noise ratios in the optical imaging modality. Other studies have used bimodal 18 F-labeled and fluorescent PET tracers with specific activities 93 Ci/μmol [40] . Here, the uptake of radiotracer could not be correlated to the optical imaging agent unless cold fluorescent tracer was co-injected [40] . This illustrates that for bimodal parallel imaging of optical and radiolabeled probes, the specific activities might have to be adjusted to the less sensitive imaging modality.
In U87 MG glioblastoma xenograft-bearing mice, 18 FPARPi-FL was rapidly cleared from all organs via the liver, suggesting that the major excretion pathway occurs via hepatobiliary clearance, similar to what is observed for the parent molecule Olaparib [41, 42] and other [
18 F]BODIPY tracers [43] . One drawback of [ 18 F]PARPi-FL was in the quick metabolic defluorination of the tracer, which results in increased bone uptake (Fig. 5d , e, Table S2 ). This is in agreement with the known chemistry of BODIPY dyes [44, 45] . Defluorination might limit the broad applicability of the imaging agent. However, the rate of defluorination and the resulting bone uptake might be reduced in vivo by addition of cytochrome P450 isozyme 2E1 (CYP2E1) inhibitors, similar to what has been shown before [46] [47] [48] . Nevertheless, we were able to show that [
18 F]PARPi-FL is a potentially valuable, clinically relevant bimodal contrast agent that fuses optical and PET imaging, combining the advantages of whole-body and high-resolution imaging.
Conclusion
This study presents the automated synthesis of a fluorescent/ radiolabeled small molecule for imaging of PARP1 in vivo-using both epifluorescence and whole-body imaging techniques. We present here an optimized and automated synthesis of this bimodal tracer as well as its in vivo properties. The fluorescent sister imaging agent PARPi-FL has been previously demonstrated to be a valuable and selective probe [23] [24] [25] . Our radiolabeled, but otherwise structurally identical bimodal version of PARPi-FL, [ 18 F]PARPi-FL, has proven to maintain similar specific binding properties to PARP1 in vivo with a comparable uptake and retention behavior to the non-radiolabeled version of the probe.
Radiolabeled fluorescent [ 18 F]PARPi-FL possesses ideal pharmacokinetic properties to detect and interrogate tumor growth and treatment success. It represents a fusion of two widely used imaging technologies in laboratory and diagnostic medicine-PET and fluorescence imaging. The use of a PARP1 imaging agent is particularly valuable for investigating malignant growth in the brain because of the low PARP1 expression in healthy brain tissue that facilitates particularly high signal/noise ratios [17, 21, 22, 46, 47] .
In conclusion, we have successfully automated and tested the first PARP1-targeted bimodal imaging agent. We believe that this imaging agent could become useful as an intraoperative fluorescent tool for glioblastoma, where the fluorescent component of [
18 F]PARPi-FL will allow cellular resolution point-of-care imaging to accurately and noninvasively interrogate surgical margins. At the same time, the radiolabeled component of [
18 F]PARPi-FL allows for detection of deep-seated lesions below the tissue surface and might be useful in planning radiation treatment. Ultimately, this agent may fulfill unmet clinical needs and assist in the clinical decision-making process.
